The Experimental Irradiator Core maintains and operates sources of ionizing and non-ionizing radiation for use of Cancer Center members in their experimental studies. Studies performed by the resource staff include advice to users on design of experiments using radiation, training in operation of the sources, scheduling use of the resources, operating the resources when necessary, dosimetry for new experimental setups, and maintenance and repair of the resources. When not in use by members, these facilities and services are also available to non-members on an increased fee-basis. The primary resources of the facility are four Cs-137 irradiators that deliver ionizing radiation. Two Nordion Gammacell 40 irradiators are primarily used for whole-body irradiation of rodents and cell cultures at a constant dose rate. The Shepherd Mark I irradiator is primarily used to deliver radiation to animal tumors at doses compared to those used clinically in external beam radiotherapy or to sterilized cell cultures or other experimental samples. The low-dose-rate-irradiator, built-in-house, is used to deliver radiation to cell cultures and rodents in dose-rates similar to those used in tumor therapy using radioactive implants, and has been used in studies of carcinogenic processes by low- dose-rate radiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-39
Application #
6474062
Study Section
Project Start
1978-01-01
Project End
2006-04-30
Budget Start
Budget End
Support Year
39
Fiscal Year
2001
Total Cost
$189,195
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225

Showing the most recent 10 out of 2393 publications